Remove 2019 Remove Communication Remove Labelling
article thumbnail

FDA-Approved Labeling: Is Enough Enough?

The FDA Law Blog

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts.

article thumbnail

Hard times at Ardelyx as FDA rejects kidney disease drug tenapanor

pharmaphorum

The US regulator had extended its review of the drug by three months – setting back its action date from April to 29 July – but now says that deficiencies in the marketing application “preclude discussion” of labelling and post-marketing requirements. “Despite….advantageous

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

The FDA Law Blog

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Medical information about a patient. Other medical information.

FDA 52
article thumbnail

Can a nasal spray tackle agitation in autism?

Pharmaceutical Technology

Dr Jeremy Veenstra-VanderWeele, professor of developmental neuropsychiatry at the Columbia University Irving Medical Center, explains that agitation is seen in the minority of autistic teens, who struggle with communication. An inability to clearly communicate with others and express their wants and needs results in frustration, he adds.

article thumbnail

Cyberbullying statistics 2022

The Checkup by Singlecare

Google Survey , 2019). The Cyberbullying Research Center , 2019). The Cyberbullying Research Center , 2019). The Cyberbullying Research Center , 2019). UNICEF Poll , 2019). high school students experienced cyberbullying in 2019. In another survey in 2019, 15.7% Ditch the Label , 2017).

article thumbnail

FDA holds back from action over Xeljanz safety study

pharmaphorum

The study was carried out at the request of the FDA, after concerns emerged about the safety of Xeljanz which emerged in 2019, and specifically a possible increased risk of blood clots in the lungs and death, particularly with the higher 10mg approved dose of the drug.

FDA 78
article thumbnail

Gabapentin interactions to avoid

The Checkup by Singlecare

Available under the brand names Neurontin , Gralise , and Horizant , gabapentin is also commonly prescribed off-label for general nerve pain, migraines , and bipolar disorder. Off-label use is when a drug is used for a purpose other than what it is approved for. Side effects of CNS depressants include drowsiness and trouble breathing.